Click Therapeutics, a healthcare technology company offering prescription digital therapeutics and software-enhanced drug therapies, secured a round of Series C funding from Dassault Systèmes. The company develops software as prescription medical treatments for patients with unmet needs.
Click Therapeutics’ platform-based approach to medicine combines scientifically proven therapies and neuromodulatory mechanisms of action. The company’s prescription mobile apps are regulated, clinically validated and designed to address therapeutic needs across psychiatry, neurology, oncology, immunology and cardiometabolic diseases.
The investment furthers the relationship between Click Therapeutics and Dassault Systèmes’ Medidata brand, allowing the two companies to improve patient engagement throughout the clinical process and advance the patient experience with end-to-end technology solutions.
Backed by its new funding, Click Therapeutics will gain access to Dassault Systèmes’ global network to support its development of new therapies. The funding round amount was not disclosed.
